Inhibition of nuclear factor kappa B activation in early-stage chronic lymphocytic leukemia by omega-3 fatty acids

Cancer Investigation

Volumn 31, Issue 1, 2013, Pages 24-38

  Fahrmann, Johannes F ^a   Ballester, Oscar F ^a   Ballester, Gabriela ^a   Witte, Theodore R ^a   Salazar, Alexander J ^a   Kordusky, Benjamin ^b   Cowen, Kelsey G ^c   Ion, Gabriela ^a   Primerano, Donald A ^a   Boskovic, Goran ^a   Denvir, James ^a   Hardman, W Elaine ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEST VIRGINIA WESLEYAN COLLEGE   (United States)

^c CEDARVILLE UNIVERSITY   (United States)

Author keywords

Cancer prevention; Clinical trials; Leukemias

Indexed keywords

DOXORUBICIN; FISH OIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OMEGA 3 FATTY ACID; MESSENGER RNA;

ADULT; ARTICLE; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SUPPLEMENTATION; THROMBOCYTE FUNCTION; AGED; BLOOD; CLINICAL TRIAL; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; THROMBOCYTE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BLOOD PLATELETS; DIETARY SUPPLEMENTS; DOXORUBICIN; FATTY ACIDS, OMEGA-3; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTES; MALE; MIDDLE AGED; NF-KAPPA B; RNA, MESSENGER;

EID: 84872694852     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.743553     Document Type: Article

References (54)

1. Robak T. Recent progress in the management of chronic lymphocytic leukemia. Cancer Treat Rev 2007;33(8):710-728 (Pubitemid 350089291)
2. Shanafelt TD, Call TG. Current approach to diagnosis and management of chronic lymphocytic leukemia. Mayo Clin Proc 2004;79(3):388-398 (Pubitemid 38269240)
3. Balkwill F, Coussens LM. Cancer: An inflammatory link. Nature 2004;431(7007):405-406 (Pubitemid 39329565)
4. Darnell JE, Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2(10):740-749 (Pubitemid 37328909)
5. Clevers H. At the crossroads of inflammation and cancer. Cell 2004;118(6):671-674 (Pubitemid 39221727)
6. Munzert G, Kirchner D, Stobbe H, Bergmann L, Schmid RM Döhner H, Heimpel H. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: Analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 2002;100(10):3749-3756 (Pubitemid 35303947)
7. Cilloni D, Martinelli G, Messa F, Baccarani M, Saglio G. Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica 2007;92(9):1224-1229 (Pubitemid 350144181)
8. Ditsworth D, Zong WX. NF-kappaB: Key mediator of inflammation-associated cancer. Cancer Biol Ther 2004;3(12):1214-1216 (Pubitemid 41350955)
9. Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P, Kroemer G. Targeting NF-kappaB in hematologicmalignancies. Cell Death Differ 2006;13(5):748-758
10. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF Karin M, Kipps TJ. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109(2):703-710 (Pubitemid 46105972)
11. Cilloni D, Messa F, Arruga F, Defilippi I, Morotti A, Messa E Carturan S, Giugliano E, Pautasso M, Bracco E, Rosso V, Sen A, Martinelli G, Baccarani M, Saglio G.The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006;20(1):61-67
12. Hewamana S, Lin TT, Rowntree C,KarunanithiK, Pratt G,Hills R Fegan C, Brennan P, Pepper C. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J ClinOncol 2009, 27(5), 763-769
13. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT,Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111(9):4681-4689
14. Simopoulos AP. Human requirement for N-3 polyunsaturated fatty acids. Poult Sci 2000;79(7):961-970
15. Simopoulos AP.The importance of the ratio of omega-6/omega-3
16. essential fatty acids. Biomed Pharmacother 2002;56(8):365-379
17. Simopoulos AP. Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 1991;54:438-463 (Pubitemid 21898954)
18. Bougnoux P, Germain E, Chaj̀es V, Hubert B, Lhuillery C, Le Floch O, Body G, Calais G. Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Br J Cancer 1999;79(11):1765-1769 (Pubitemid 29132302)
19. Hardman WE. Omega-3 fatty acids to augment cancer therapy. J Nutr 2002;132:3508S-3512S (Pubitemid 35315828)
20. HardmanW.E; MoyerMP, Cameron IL. Small amounts of a concentrated omega-3 fatty acid product, INCELL AAFA, in the diet reduces the side-effects of the cancer chemotherapy drug, CPT-11 (irinotecan). Br J Cancer 2002;86:983-988
21. Hyde CA,Missailidis S. Inhibition of arachidonic acidmetabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 2009;9(6):701-715
22. Narayanan NK, Narayanan BA, Reddy BS. A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int J Oncol 2005;26(3):785-792
23. Ross JA, Maingay JP, Fearon KC, Sangster K, Powell JJ. Eicosapentaenoic acid perturbs signalling via the NFkappaB transcriptional pathway in pancreatic tumour cells. Int J Oncol 2003;23(6):1733-1738
24. Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ Lester E, Kirshner JJ, Vinciguerra V, Paskett E. Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: Cancer and leukemia group B Study 9473. Clin Cancer Res 1999;5:3842-3947
25. Silber R, Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR, Morse L, Drygas JC, Canellakis ZN, Potmesil M. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 1994;84(10):3440-3446 (Pubitemid 24352908)
26. Witte TR, Salazar AJ, Ballester OF, HardmanWE. RBC and WBC fatty acid composition following consumption of an omega 3
27. supplement: Lessons for future clinical trials. Lipids Health Dis 2010;9:31
28. Shantha NC, Ackman RG. Nervonic acid versus tricosanoic acid as internal standards in quantitative gas chromatographic analyses of fish oil longer-chain n-3 polyunsaturated fatty acid methyl esters. J Chromatogr 1990;533:1-10
29. HardmanWE, IonG. Suppression of implantedMDA-MB 231 human breast cancer growth in nude mice by dietary walnut. Nutr Cancer 2008;60(5):666-674
30. Huang Y, Ou Q, YuW. Characteristics of flame ionization detection for the quantitative analysis of complex organicmixtures.Analyt Chem. 1990;62:2063-2064
31. William WC. Gas chromatographic analysis of fatty acid derivatives. Lipid Technol 1989;3:97-98
32. Syed HA, Threadgill DW. Enhanced oligonucleotide microarray labeling and hybridization. Biotechniques 2006;41(6):685- 686 (Pubitemid 46534849)
33. Tusher VG, Tibshirani R, Chu G. Significance analysis ofmicroarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98(9):5116-5121 (Pubitemid 32397092)
34. Harper CR, EdwardsmMJ, DeFilippis AP, Jacobson TA. Flaxseed oil increases the plasma concentrations of cardioprotective (n-3 fatty acids in humans. J Nutr 2006;136(1):83-87 (Pubitemid 43156489)
35. KeatingGM. Rituximab: A reviewof its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70(11):1445-1476
36. HardmanWE,Moyer MP, Cameron IL. Dietary fish oil sensitizes A549 lung xenografts to doxorubicin chemotherapy. Cancer Lett 2000;151:145-151 (Pubitemid 30156788)
37. HardmanWE, Moyer MP, Cameron IL. Fish oil supplementation enhanced CPT-11 (Irinotecan) efficacy againstMCF7 breast carcinoma xenografts and ameliorated intestinal side effects. Br J Cancer 1999;81:440-448 (Pubitemid 29458797)
38. Doubek M, Mayer J, Obrtl'ikov'a P, Smolej L, Cmunt E, Schwarz J, Brejcha M, Kozmon P, Posp'isilov'a S, Brychtov'a Y, Posp'isil Z, Trnan'y M. Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. Eur J Haematol 2011;87(2):130-137
39. Mougalian SS, O'Brien S. Adverse prognostic features in chronic lymphocytic leukemia. Oncology (Williston Park ;25(8):692-696, 699
40. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P Desablens B, Rapp MJ, Jaubert J, Autrand C, Divine M, Dreyfus B, Maloum K, Travade P, Dighiero G, Binet JL, Chastang C. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-2325
41. Li F, Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010;1805(2):167-180
42. Katoh M. Comparative integromics on JMJD1C gene encoding histone demethylase: Conserved POU5F1 binding site elucidating mechanismof JMJD1Cexpression inundifferentiatedES cells and diffuse-type gastric cancer. Int J Oncol 2007;31(1):219-223
43. Shur I, Socher R, Benayahu D. In vivo association of CReMM/CHD9 with promoters in osteogenic cells. J Cell Physiol 2006;207(2):374-378
44. Marom R, Shur I, Hager GL, Benayahu D. Expression and regulation of CReMM, a chromodomain helicase-DNA-binding (CHD), in marrow stroma derived osteoprogenitors. J Cell Physiol 2006;207(3):628-635 (Pubitemid 43668224)
45. An S, Yeo KJ, Jeon YH, Song JJ. Crystal structure of the human histone methyltransferase ASH1L catalytic domain and its implications for the regulatory mechanism. J Biol Chem 2011;286(10):8369-8374
46. Harrison BC, Huynh K, Lundgaard GL, Helmke SM, Perryman MB, McKinseym TA. Protein kinase C-related kinase targets nuclear localization signals in a subset of class IIa histone deacetylases. FEBS Lett 2010;584(6):1103-1110
47. Park JT, Chen X, Trope CG, Davidson B, Shih I, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol 2010;177(3):1087-1094
48. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, CoenenMJ Franke B, Franke L, PosthumusMD, van Heel DA, van der Steege G, Radstake TR, Barrera P, Roep BO, Koeleman BP Wijmenga C. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007;81(6):1284-1288 (Pubitemid 350211457)
49. PardoM, Lang B, Yu L, ProsserH, Bradley A, BabuMM, Choudhary J. An expanded Oct4 interaction network: Implications for stem cell biology, development, and disease. Cell Stem Cell 2010;6(4):382-395
50. Hoeller S, Walz C, Reiter A, Dirnhofer S, Tzankov A. PCM1- JAK2-fusion: A potential treatment target in myelodysplasticmyeloproliferative and other hemato-lymphoid neoplasms. Expert Opin Ther Targets 2011;15(1):53-62
51. Kuefer MU, Chinwalla V, Zeleznik-Le NJ, Behm FG, Naeve CW, Rakestraw KM, Mukatira ST, Raimondi SC, Morris SW. Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14). Oncogene 2003;22(9):1418-1424 (Pubitemid 36384604)
52. Bogdanov K, Takimoto M. The involvement of c-Abl and D40 (AF15q14/CASC5) proteins in the regulation of cell proliferation and cancer. Tsitologiia 2008;50(7):590-596
53. Takimoto M, Wei G, Dosaka-Akita H, Mao P, Kondo S, Sakuragi N, Chiba I, Miura T, Itoh N, Sasao T, Koya RC, Tsukamoto T Fujimoto S, Katoh H, Kuzumaki N. Frequent expression of new cancer/testis gene D40/AF15q14 in lung cancers of smokers. Br J Cancer 2002;86(11):1757-1762 (Pubitemid 34716236)
54. Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007;120(4):796-805 (Pubitemid 46175399)